Monte Rosa Therapeutics, Inc.
GLUE
$15.50
-$0.34-2.15%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.97M | 4.21M | 2.78M | 12.77M | 23.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.97M | 4.21M | 2.78M | 12.77M | 23.19M |
| Cost of Revenue | 45.99M | 41.83M | 39.89M | 34.65M | 29.05M |
| Gross Profit | -37.02M | -37.62M | -37.11M | -21.88M | -5.85M |
| SG&A Expenses | 12.11M | 12.42M | 12.60M | 11.09M | 9.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.10M | 54.24M | 52.50M | 45.74M | 38.75M |
| Operating Income | -49.13M | -50.03M | -49.72M | -32.98M | -15.55M |
| Income Before Tax | -43.19M | -44.45M | -46.08M | -30.26M | -11.10M |
| Income Tax Expenses | 208.00K | 52.00K | 59.00K | -3.18M | 1.20M |
| Earnings from Continuing Operations | -43.40M | -44.50M | -46.14M | -27.08M | -12.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.40M | -44.50M | -46.14M | -27.08M | -12.30M |
| EBIT | -49.13M | -50.03M | -49.72M | -32.98M | -15.55M |
| EBITDA | -47.22M | -48.01M | -47.63M | -30.88M | -13.43M |
| EPS Basic | -0.43 | -0.45 | -0.54 | -0.33 | -0.15 |
| Normalized Basic EPS | -0.27 | -0.28 | -0.34 | -0.23 | -0.08 |
| EPS Diluted | -0.43 | -0.45 | -0.54 | -0.33 | -0.15 |
| Normalized Diluted EPS | -0.27 | -0.28 | -0.34 | -0.23 | -0.08 |
| Average Basic Shares Outstanding | 101.48M | 99.88M | 85.55M | 82.40M | 82.19M |
| Average Diluted Shares Outstanding | 101.48M | 99.88M | 85.55M | 82.40M | 82.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |